Physician profile
Efrain Rivera
NPI 1780780858
$11,178.28
in general payments reported to CMS, 2019-2025
38 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $626 · 2021: $3,406 · 2022: $1,983 · 2023: $743 · 2024: $2,742 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,384 · Food and Beverage: $2,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,383.82 |
| Food and Beverage | $2,076.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,075.84 | 2021-2025 | Proclaim, Eterna, Ionicrf |
| Spinal Simplicity, LLC | $2,192.95 | 2021-2022 | |
| Si-Bone, INC. | $1,181.19 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $533.20 | 2019-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $416.91 | 2019-2022 | |
| Abbvie INC. | $352.29 | 2021-2024 | Ubrelvy, Qulipta |
| Amgen INC. | $337.41 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $301.90 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $280.19 | 2022 | |
| Pfizer INC. | $268.90 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $268.77 | 2020-2023 | Belbuca |
| Medtronic, INC. | $251.49 | 2022-2023 | Accurian |
| Redhill Biopharma INC. | $208.30 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.26 | 2021-2025 | Relistor |
| Daiichi Sankyo INC. | $185.53 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $133.40 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.51 | 2021 | |
| Nevro Corp. | $117.38 | 2024 | Senza |
| Nalu Medical, INC. | $112.11 | 2022-2025 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $65.96 | 2024 | Qutenza |
| Depuy Synthes Sales INC. | $57.01 | 2019-2023 | Orthovisc |
| Fidia Pharma USA INC. | $56.25 | 2019 | |
| Horizon Therapeutics Plc | $47.29 | 2022 | |
| Allergan, INC. | $46.58 | 2020 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Bioventus LLC | $37.23 | 2020-2023 | Durolane |
| Takeda Pharmaceuticals U.S.A., INC. | $36.63 | 2019 | |
| Eisai INC. | $33.92 | 2021 | |
| Stryker Corporation | $33.69 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.95 | 2025 | |
| Pacira Therapeutics, INC. | $23.29 | 2021 | |
| Lundbeck LLC | $21.65 | 2023 | Vyepti |
| Idorsia Pharmaceuticals US INC | $19.47 | 2023 | Quviviq |
| Lilly USA, LLC | $19.35 | 2021 | |
| Curonix LLC | $17.30 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Arbor Pharmaceuticals, INC. | $16.09 | 2021 | |
| Ibsa Pharma INC. | $14.15 | 2023 | Tirosint, Licart |
| Mdd US Operations, LLC | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.